Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study

NCT03447808 is registered in ClinicalTrials.gov with Jennifer Woyach as lead sponsor.

NCT NCT03447808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03447808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study
Lead sponsor
Jennifer Woyach
Phase
Phase 1
Overall status
Completed
Start date
August 16, 2018
Completion date
May 26, 2026
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia